References of "REGINSTER, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailUncoupling of bone formation and resorption with a novel oral formulation of salmon calcitonin in postmenopausal women
Tanko, L. B.; Bagger, Y. Z.; Devogelaer, Jean-Pierre et al

in Osteoporosis International (2003, November), 14(Suppl. 7), 4

Detailed reference viewed: 9 (0 ULg)
Full Text
Peer Reviewed
See detailEvaluation of an osteoporosis screening campaign in the general population: does misclassification by screening test impact on the perception of the campaign?
Richy, Florent; Pire, G.; Maassen, P. et al

in Osteoporosis International (2003, November), 14(Suppl. 7), 68

Detailed reference viewed: 11 (2 ULg)
Full Text
Peer Reviewed
See detailAvocado/soybean unsaponifiables reverse H2O2 decoupling effect on aggrecan, type II collagen and metalloproteases gene expression in human chondrocytes
Mathy, Marianne ULg; Devel, P.; Piccardi, Nathalie et al

in Osteoarthritis and Cartilage (2003, October), 11(Suppl.1), 99

Detailed reference viewed: 11 (2 ULg)
Full Text
Peer Reviewed
See detailAdvocado/soybean unsaponifiables decrease the expression of pro-inflammatory genes in human chondrocytes
Mathy, Marianne ULg; Devel, P.; Piccardi, Nathalie et al

in Osteoarthritis and Cartilage (2003, October), 11(Suppl.1), 97-98

Detailed reference viewed: 11 (5 ULg)
Full Text
Peer Reviewed
See detailInfluence of oxygen tension on nitric oxide and prostaglandin E2 production by bovine chondrocytes
Burton, Sandrine; Mathy, Marianne ULg; Deby-Dupont, Ginette et al

in Osteoarthritis and Cartilage (2003, October), 11(Suppl.1), 58

Detailed reference viewed: 8 (4 ULg)
Full Text
Peer Reviewed
See detailFive-year follow-up of patients from a previous 3-year randomised, controlled trial of glucosamine sulfate in knee osteoarthritis
Bruyère, Olivier ULg; Compere, S.; Rovati, Lucio C et al

in Osteoarthritis and Cartilage (2003, October), 11(Suppl.1), 10-11

Detailed reference viewed: 19 (1 ULg)
Full Text
Peer Reviewed
See detailCartilage degradation and oxidative damage in osteoarthritic and rheumatoid arthritic patients
Deberg, Michelle ULg; Labasse, Alain ULg; Christgau, Stephan et al

in Osteoarthritis and Cartilage (2003, October), 11(Suppl.1), 15

Detailed reference viewed: 13 (2 ULg)
Full Text
Peer Reviewed
See detailRelief in mild-to-moderate pain is not a confounder in joint space narrowing assessment of full extension knee radiographs in recent osteoarthritis structure-modifying drug trials
Pavelka, K.; Bruyère, Olivier ULg; Rovati, Lucio C et al

in Osteoarthritis and Cartilage (2003), 11(10), 730-737

Objective: To assess whether improvement in knee pain biased the determination of the structure-modifying effect reported for glucosamine sulfate in two recent 3-year, randomised, placebo-controlled ... [more ▼]

Objective: To assess whether improvement in knee pain biased the determination of the structure-modifying effect reported for glucosamine sulfate in two recent 3-year, randomised, placebo-controlled clinical trials, in which conventional standing antero-posterior full extension knee radiographs were used for the measurement of joint space narrowing, and in which pain relief might have improved knee full extension. Design: Patients completing the 3-year treatment course were selected based on a WOMAC pain decrease at least equal to the mean improvement in the glucosamine sulfate arms in either of the original studies, irrespective of treatment with glucosamine sulfate or placebo (drug responders or placebo responders). In a second approach, 3-year completers were selected if their baseline standing knee pain (item #5 of the WOMAC pain scale) was 'severe' or 'extreme' and improved by any degree at the end of the trials. In both cases, changes in minimum joint space width were compared between treatment groups. Results: Global knee pain was rnild-to-moderate in the two study populations and in all patient subsets identified. There were obviously more pain improvers in the glucosamine sulfate subsets (N=76 in the two studies combined) than in the placebo subsets (N=57), but WOMAC pain scores improved to the same extent, which was as large as over 50% relative to baseline. Nevertheless, the placebo subsets in both studies underwent an evident mean (SD) joint space narrowing, which in the pooled analysis of both studies was -0.22 (0.80) mm, and was not observed with glucosamine sulfate: +0.15 (0.60) mm (P=0.003 vs placebo). Similar results were found in the smaller subsets with greater than or equal to severe baseline standing knee pain that improved after 3 years, with a joint space narrowing nevertheless of -0.28 (0.76) mm with placebo (N=26), not observed with glucosamine sulfate: +0.21 (0.68) mm (N=31; P=0.014 vs placebo). Conclusions: Knee pain relief did not bias the report of a structure-modifying effect of glucosamine sulfate in two recent long-term trials using conventional standing antero-posterior radiographs, possibly due to the mild-to-moderate patient characteristics. (C) 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved. [less ▲]

Detailed reference viewed: 38 (2 ULg)
Full Text
Peer Reviewed
See detailNaturocetic (glucosamine and chondroitin sulfate) compounds as structure-modifying drugs in the treatment of osteoarthritis
Reginster, Jean-Yves ULg; Bruyère, Olivier ULg; Lecart, Marie-Paule ULg et al

in Current Opinion in Rheumatology (2003), 15

Purpose of review Several entities have been investigated carefully for the symptomatic and structural management of osteoarthritis. This review reports recent findings suggesting that such compounds may ... [more ▼]

Purpose of review Several entities have been investigated carefully for the symptomatic and structural management of osteoarthritis. This review reports recent findings suggesting that such compounds may delay the structural progression of osteoarthritis. Recent findings The most compelling evidence of a potential for inhibiting the structural progression of osteoarthritis has been obtained with glucosamine sulfate, whereas preliminary results obtained in patients with osteoarthritis of the hands also suggest that chondroitin sulfate could be used in the same indication. At any rate, these two compounds have clearly demonstrated a symptomatic action, mainly in osteoarthritis of the lower limbs. Patients with the less severe radiographic osteoarthritis will experience, in the long run, the most dramatic disease progression in terms of joint space narrowing. Such patients may be particularly responsive to structure-modifying drugs. Summary Glucosamine sulfate has demonstrated its ability to reduce the progression of osteoarthritis in the lower limbs. The preliminary results obtained in the hands suggest that chondroitin sulfate could also be of interest in this indication. An important issue is that all the conclusive studies with such chemical entities resulted from the use of prescription medicines, not over-the-counter pills or food supplements. [less ▲]

Detailed reference viewed: 42 (8 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis prevalence estimates for men: variation based on normative data
Gourlay, Margaret L; Richy, Florent; Garrett, Joanne et al

in Arthritis and Rheumatism (2003, September), 48(number 9 (suppl.)), 298

Detailed reference viewed: 9 (0 ULg)
Full Text
Peer Reviewed
See detailRisk assessment tools for osteoporosis: Scope and limits
Richy, Florent; Gourlay, Margaret; Ross, Philip D et al

in Arthritis and Rheumatism (2003, September), 48(number 9 (suppl.)), 215

Detailed reference viewed: 14 (4 ULg)
Full Text
Peer Reviewed
See detailEfficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate
Richy, Florent Y; Reginster, Jean-Yves ULg

in Arthritis and Rheumatism (2003, September), 48(number 9 (suppl.)), 214

Detailed reference viewed: 5 (0 ULg)
Full Text
Peer Reviewed
See detailStructural and symptomatic efficacy of glucosamine and chondroitine sulfate in osteoarthritis: a comprehensive meta-analysis
Richy, Florent Y; Bruyère, Olivier ULg; Ethgen, Olivier ULg et al

in Arthritis and Rheumatism (2003, September), 48(number 9 (suppl.)), 214

Detailed reference viewed: 22 (2 ULg)
Full Text
Peer Reviewed
See detailFive-year follow-up of patients from a previous 3-year randomised, controlled trial of glucosamine sulfate in knee osteoarthritis
Bruyère, Olivier ULg; Compere, Stephanie; Rovati, Lucio C et al

in Arthritis and Rheumatism (2003, September), 48(number 9 (suppl.)), 80

Detailed reference viewed: 30 (0 ULg)
Full Text
Peer Reviewed
See detailControlled whole body vibrations improve health related quality of life in elderly patients
Bruyère, Olivier ULg; Wuidart, Marc-Antoine; Di Palma, Elio et al

in Arthritis and Rheumatism (2003, September), 48(9, Suppl. S), 502

Detailed reference viewed: 72 (9 ULg)
Full Text
Peer Reviewed
See detailStrategies for the prevention of hip fracture
Gourlay, M.; Richy, F.; Reginster, Jean-Yves ULg

in American Journal of Medicine (2003), 115(4), 309-317

Hip fractures are associated with 10% to 20% excess mortality in the first year and cause functional disability in most survivors. An estimated 17% of white women in the United States will sustain a hip ... [more ▼]

Hip fractures are associated with 10% to 20% excess mortality in the first year and cause functional disability in most survivors. An estimated 17% of white women in the United States will sustain a hip fracture after the age of 50 years. Despite the availability of evidence-based guidelines for hip fracture prevention, routine screening and preventive measures have not been incorporated into standard primary care practice. Many physicians lack adequate knowledge to initiate bone mineral density testing and treatment with preventive medications to decrease the incidence of osteoporosis and fractures. Furthermore, patients are less likely to request information about bone health than about diseases for which systematic screening and prevention protocols have been established. This review describes preventive measures to decrease hip fracture in postmenopausal women, including screening by bone mineral density testing, risk factor assessment, and chemoprevention. Existing guidelines are summarized, and dilemmas regarding their implementation are discussed. (C) 2003 by Excerpta Medica Inc. [less ▲]

Detailed reference viewed: 13 (0 ULg)
Full Text
Peer Reviewed
See detailEffect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial
Reginster, Jean-Yves ULg; Felsenberg, D.; Pavo, I. et al

in Osteoporosis International (2003), 14(9), 741-749

Raloxifene effectively reduces the incidence of vertebral fractures in patients with postmenopausal osteoporosis. Recent data suggest that low-dose monofluorophosphate (MFP) plus calcium reduces the ... [more ▼]

Raloxifene effectively reduces the incidence of vertebral fractures in patients with postmenopausal osteoporosis. Recent data suggest that low-dose monofluorophosphate (MFP) plus calcium reduces the vertebral fracture rate in postmenopausal women with moderate osteoporosis. The objective of this study was to evaluate the combination of raloxifene and MFP in the treatment of postmenopausal women with osteopenia, osteoporosis and severe osteoporosis. A total of 596 postmenopausal women with osteopenia, osteoporosis and severe osteoporosis (mean femoral neck T-score of -2.87 SD) were randomized to treatment with 60 mg/day raloxifene HCl and 20 mg/day fluoride ions (as MFP) or 20 mg/day fluoride and placebo for 18 months. All patients received calcium (1000 mg/day) and vitamin D (500 IU/day) supplements. Changes in bone mineral density (BMD), as primary endpoint, and the rate of osteoporotic fractures and biochemical markers, as secondary endpoints, were assessed. As compared with MFP, raloxifene plus MFP was associated with significantly greater mean increases in the BMD of the femoral neck (1.37% versus 0.33%; P=0.004), total hip (0.89% versus -0.42%; P<0.001) and lumbar spine (8.80% versus 5.47% P<0.001). In the raloxifene plus MFP group, 16 patients sustained 17 osteoporotic fractures, as compared with 22 patients sustaining 34 incident osteoporotic fractures in the MFP group (P=0.313). One patient in the raloxifene plus MFP group sustained multiple osteoporotic fractures, as compared with eight patients in the MFP group (P=0.020). MFP alone significantly increased the serum bone alkaline phosphatase (bone ALP) and the urinary C-terminal crosslinking telopeptide of type I collagene (U-CTX). The addition of raloxifene in the combination arm blunted the rise in bone ALP, which remained nevertheless significant, and abolished the increase in U-CTX. The combination of raloxifene with MFP was generally well tolerated. This study demonstrates that, in postmenopausal women with osteopenia, osteoporosis and severe osteoporosis, the combination therapy of raloxifene plus MFP favorably influences the BMD and the bone formation and resorption balance, and may reduce the risk of multiple osteoporotic fractures compared to MFP alone. [less ▲]

Detailed reference viewed: 14 (1 ULg)
Full Text
Peer Reviewed
See detailComparison of a simple clinical risk index and quantitative bone ultrasound for identifying women at increased risk of osteoporosis
Kung, A. W. C.; Ho, A. Y. Y.; Ben Sedrine, W. et al

in Osteoporosis International (2003), 14(9), 716-721

Osteoporosis is a growing problem in Asia, and early identification of at risk subjects for preventive measures is likely the most cost-effective method for managing this disease in developing countries ... [more ▼]

Osteoporosis is a growing problem in Asia, and early identification of at risk subjects for preventive measures is likely the most cost-effective method for managing this disease in developing countries. Patients with low bone mineral density (BMD) have a high risk of future fracture. However, access to BMD measurements is limited in many areas of Asia, and inexpensive methods of targeting high-risk patients for BMD measurements would be valuable. We compared two methods, a simple clinical risk assessment tool, the Osteoporosis Self-assessment Tool for Asians (OSTA), and quantitative bone ultrasound (QUS) in identifying subjects with low BMD by DXA in 722 southern Chinese postmenopausal women recruited from the community in Hong Kong. Using the published cutoff value of -1 (versus 0 or higher) for OSTA to identify subjects with femoral neck BMD T-score less than or equal to-2.5, basing on our local population peak young mean value, the sensitivity and specificity was 88% and 54% respectively. The optimal cutoff T-score of -2.35 for QUS yielded sensitivity and specificity values of 81% and 65%, respectively. The AUC for QUS was 0.78, which was not significantly different from that of 0.80 for OSTA. Both OSTA and QUS correlated significantly with BMD at the femoral neck (0.62 and 0.36, respectively, P both <0.001). When these cut-off values were used to identify subjects with either lumbar spine or femoral neck BMD T-score less than or equal to-2.5, the sensitivity and specificity was 79% and 60%, respectively, for OSTA, and 69% and 70%, respectively, for QUS. Combining QUS with OSTA improved the sensitivity to 91%, but the specificity was reduced to 44%. We conclude that the simple clinical risk assessment tool OSTA is a free and effective method for identifying subjects at increased risk of osteoporosis, and its use could facilitate the appropriate and more cost-effective use of bone densitometry in developing countries. [less ▲]

Detailed reference viewed: 34 (0 ULg)
Full Text
Peer Reviewed
See detailNew perspectives in the management of osteoarthritis. Structure modification: Facts or fantasy?
Reginster, Jean-Yves ULg; Bruyère, Olivier ULg; Henrotin, Yves ULg

in Journal of Rheumatology. Supplement (2003), 67(Suppl. 67), 14-20

Several entities have been carefully investigated for the symptomatic and structural management of osteoarthritis (OA). The most compelling evidence of a potential for inhibiting the structural ... [more ▼]

Several entities have been carefully investigated for the symptomatic and structural management of osteoarthritis (OA). The most compelling evidence of a potential for inhibiting the structural progression of OA has been obtained with glucosamine sulfate, while some preliminary results also suggest that other compounds could be used in the same indication. At any rate, several medications have clearly demonstrated a symptomatic action, mainly in OA of the lower limbs, including pain relief and improvement of functional disability. An important issue is that all conclusive studies with such chemical entities resulted from the use of prescription medicines and not over-the-counter or nutriceutical supplements. [less ▲]

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailAvocado/soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and proinflammatory mediator production by human osteoarthritic chondrocytes
Henrotin, Yves ULg; Sanchez, Christelle ULg; Deberg, Michelle ULg et al

in Journal of Rheumatology (2003), 30(8), 1825-1834

OBJECTIVE: To investigate the effects of avocado (A)/soybean (S) unsaponifiables on the metabolism of human osteoarthritic (OA) chondrocytes cultured in alginate beads over 12 days. METHODS: Enzymatically ... [more ▼]

OBJECTIVE: To investigate the effects of avocado (A)/soybean (S) unsaponifiables on the metabolism of human osteoarthritic (OA) chondrocytes cultured in alginate beads over 12 days. METHODS: Enzymatically isolated OA chondrocytes were cultured in alginate beads in a well defined culture medium for 12 days, in the presence or not of 10-10 M interleukin 1beta (IL-1beta). DNA content was measured using a fluorometric method. Production of aggrecan (AGG), stromelysin-1 (MMP-3), tissue inhibitor of metalloproteinases-1 (TIMP-1), macrophage inflammatory protein-1beta (MIP-1beta), IL-6, and IL-8 were assayed by specific enzyme amplified sensitivity immunoassays. Prostaglandin (PG) E2 was measured by a specific radioimmunoassay and nitrite by a spectrophotometric method based on the Griess reaction. A commercial avocado and soybean mixture of unsaponifiables (A1S2) and each component separately were tested in a range of 0.625 to 40.0 micro g/ml. RESULTS: After 12 days' incubation, A1S2 increased AGG synthesis and accumulation in alginate beads in a dose and time dependent manner. A1S2 promoted the recovery of aggrecan synthesis after 3 days of IL-1beta treatment. A1S2 was a potent inhibitor of basal and IL-1beta stimulated MMP-3 production. The procedure also weakly reversed the inhibitory effect of IL-1beta on TIMP-1 production. A1S2 inhibited basal production of MIP-1beta, IL-6, IL-8, NO*, and PGE2 by OA chondrocytes and partially counteracted the stimulating effect of IL-1 on PGE2. Compared to avocado or soybean added separately, the mixture had a superior effect on NO* and IL-8 production. CONCLUSION: A1S2 stimulated aggrecan production and restored aggrecan production after IL-1beta treatment. In parallel, A1S2 decreased MMP-3 production and stimulated TIMP-1 production. These results suggest A1S2 could have structure-modifying effects in OA by inhibiting cartilage degradation and promoting cartilage repair. [less ▲]

Detailed reference viewed: 79 (16 ULg)